Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review

Table 1

Sequential changes of liver enzymes and laboratory tests for hepatitis E.

Time after admission	AST	ALT	Anti-HEV IgG	Anti-HEV IgM	Anti-HEV IgA	HEV RNA
	(13–33 IU/L^∗)	(6–27 IU/L^∗)	(OD450 < 0.175^∗)	(OD450 < 0.440^∗)	(OD450 < 0.642^∗)	(−)
−30 months	17	9	0.046	0.043	0.042	−
−20 months	16	14	0.047	0.05	0.035	−
−10 months	19	14	0.035	0.088	0.04	−
0	338	523	2.563	2.845	2.93	+
1 week	44	137	2.822	>3.000	>3.000	+
2 weeks	32	37	>3.000	2.894	2.296	+
3 weeks	22	18	2.748	2.771	1.499	+
6 weeks	27	25	2.956	2.661	1.113	−
10 weeks	22	15	>3.000	2.303	1.019	−
14 weeks	27	19	>3.000	1.863	0.799	−
22 weeks	43	28	>3.000	1.022	0.536	−
26 weeks	31	26	NA	NA	NA	NA
57 months	24	17	1.659	0.176	0.115	−

^∗Normal range. HEV, hepatitis E virus; IgG, immunoglobulin G; IgM, immunoglobulin M; IgA, immunoglobulin A; NA, not available.